A Single-Arm, Phase II, Multicenter Clinical Study of Neoadjuvant Encorafenib Plus Cetuximab N01 and mFOLFOX6 in Patients With Locally Advanced BRAF V600E-Mutan

A Single-Arm, Phase II, Multicenter Clinical Study of Neoadjuvant Encorafenib Plus Cetuximab N01 and mFOLFOX6 in Patients With Locally Advanced BRAF V600E-Mutant Colorectal Cancer With or Without Resectable Metastases is a phase 2, interventional study registered as NCT07789210 by Zhejiang University, with a registry enrolment figure of 25 participants, started 2026-06-30 and due to reach its primary completion in 2029-12-31. Interventions recorded: Neoadjuvant therapy of encorafenib plus cetuximab N01 and mFOLFOX6. Conditions listed: Colorectal Cancer; BRAF V600E Mutation Positive; Encorafenib; Cetuximab N01. Primary outcome: 18-month disease-free survival rate. Colorectal eligibility wording from the registry: "* Colorectal adenocarcinoma diagnosed by histopathology, preoperative staging: T4N0-2M0, T3N2M0, T0-4N0-2M1a (with metastatic lesions present, requiring MDT evaluation as resectable); PMMR/MSS, BRAF V600E mutation, and both NRAS and KRAS wild-type;". Sites: China. No results are recorded here; the registry entry is the source.